Using Mendelian randomization to evaluate the causal relationship between serum C-reactive protein levels and age-related macular degeneration

[1]  M. Bahlo.  Faculty of 1000 evaluation for Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. , 2018 .

[2]  P. Donnelly,et al.  The UK Biobank resource with deep phenotyping and genomic data , 2018, Nature.

[3]  P. Mitchell,et al.  Age-related macular degeneration , 2018, The Lancet.

[4]  G. Davey Smith,et al.  Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians , 2018, British Medical Journal.

[5]  P. O’Reilly,et al.  Using genetic data to strengthen causal inference in observational research , 2018, Nature Reviews Genetics.

[6]  F. Windmeijer,et al.  An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings , 2018, bioRxiv.

[7]  B. Neale,et al.  Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases , 2018, Nature Genetics.

[8]  A. Dick,et al.  C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration , 2018, Front. Immunol..

[9]  Valeriia Haberland,et al.  The MR-Base platform supports systematic causal inference across the human phenome , 2018, eLife.

[10]  A. Fletcher,et al.  Association of C-Reactive Protein Genetic Polymorphisms With Late Age-Related Macular Degeneration , 2017, JAMA ophthalmology.

[11]  Jessica M B Rees,et al.  Dissecting Causal Pathways Using Mendelian Randomization with Summarized Genetic Data: Application to Age at Menarche and Risk of Breast Cancer , 2017, Genetics.

[12]  S. Thompson,et al.  Interpreting findings from Mendelian randomization using the MR-Egger method , 2017, European Journal of Epidemiology.

[13]  Olena O Yavorska,et al.  MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data , 2017, International journal of epidemiology.

[14]  N. Sheehan,et al.  A framework for the investigation of pleiotropy in two‐sample summary data Mendelian randomization , 2017, Statistics in medicine.

[15]  Stephen Burgess,et al.  Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants , 2016, Epidemiology.

[16]  G. Davey Smith,et al.  Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator , 2016, Genetic epidemiology.

[17]  A. Salminen,et al.  Inflammation and its role in age-related macular degeneration , 2016, Cellular and Molecular Life Sciences.

[18]  Ivana K. Kim,et al.  A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants , 2015, Nature Genetics.

[19]  R. Luben,et al.  Cross Sectional and Longitudinal Associations between Cardiovascular Risk Factors and Age Related Macular Degeneration in the EPIC-Norfolk Eye Study , 2015, PloS one.

[20]  G. Davey Smith,et al.  Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression , 2015, International journal of epidemiology.

[21]  N. Timpson,et al.  Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors , 2015, European Journal of Epidemiology.

[22]  S. Thompson,et al.  Multivariable Mendelian Randomization: The Use of Pleiotropic Genetic Variants to Estimate Causal Effects , 2015, American journal of epidemiology.

[23]  G. Davey Smith,et al.  Mendelian randomization: genetic anchors for causal inference in epidemiological studies , 2014, Human molecular genetics.

[24]  R. Klein,et al.  Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. , 2014, The Lancet. Global health.

[25]  P. Visscher,et al.  Calculating statistical power in Mendelian randomization studies. , 2013, International journal of epidemiology.

[26]  A. Butterworth,et al.  Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data , 2013, Genetic epidemiology.

[27]  E. Rimm,et al.  C-reactive protein and the incidence of macular degeneration: pooled analysis of 5 cohorts. , 2013, JAMA ophthalmology.

[28]  Gabriëlle H S Buitendijk,et al.  Seven New Loci Associated with Age-Related Macular Degeneration , 2013, Nature Genetics.

[29]  J. Marchini,et al.  Fast and accurate genotype imputation in genome-wide association studies through pre-phasing , 2012, Nature Genetics.

[30]  P. Mitchell,et al.  A review and meta-analysis of the association between C-reactive protein and age-related macular degeneration. , 2011, Survey of ophthalmology.

[31]  R. Klein,et al.  Inflammation, complement factor h, and age-related macular degeneration: the Multi-ethnic Study of Atherosclerosis. , 2008, Ophthalmology.

[32]  Ivana K. Kim,et al.  Comprehensive analysis of CRP, CFH Y402H and environmental risk factors on risk of neovascular age-related macular degeneration , 2008, Molecular vision.

[33]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[34]  P. Mitchell,et al.  Circulating inflammatory markers and hemostatic factors in age-related maculopathy: a population-based case-control study. , 2007, Investigative ophthalmology & visual science.

[35]  A. Hofman,et al.  Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. , 2006, JAMA.

[36]  P. Ridker,et al.  A prospective assessment of the Y402H variant in complement factor H, genetic variants in C-reactive protein, and risk of age-related macular degeneration. , 2006, Investigative ophthalmology & visual science.

[37]  C. Owsley,et al.  The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study , 2005, British Journal of Ophthalmology.

[38]  B. Rosner,et al.  Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. , 2005, Archives of ophthalmology.

[39]  P. Jong.  Prevalence of age-related macular degeneration in the United States. , 2004 .

[40]  N. Rifai,et al.  Association between C-reactive protein and age-related macular degeneration. , 2004, JAMA.

[41]  J. J. Wang,et al.  Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. , 1995, Ophthalmology.

[42]  Benjamin Friedman,et al.  MECHANICS OF OPTIC NERVE TRACTION ON THE RETINA DURING OCULAR ROTATION: WITH SPECIAL REFERENCE TO RETINAL DETACHMENT , 1941 .

[43]  Mark B Pepys,et al.  C-reactive protein: a critical update. , 2003, The Journal of clinical investigation.

[44]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[45]  B. Berger,et al.  Efficient Bayesian mixed model analysis increases association power in large cohorts , 2014, Nature Genetics.

[46]  A. Ramé.  [Age-related macular degeneration]. , 2006, Revue de l'infirmiere.

[47]  Stephen Burgess.  RANDOMIZATION: THE USE OF PLEIOTROPIC GENETIC VARIANTS TO ESTIMATE , 2015 .